You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,968,641

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,968,641

Title:	Method to suppress the systemic toxicity of chemotherapeutic drugs
Abstract:	This invention relates to use of manuka honey in the treatment of cancer. The invention is also directed to the combination of manuka honey with other chemotherapeutic agents to reduce the toxicity of the treatment.
Inventor(s):	Al-Ramadi; Basel (Abu Dhabi, AE), El-Taji; Hakam (Abu Dhabi, AE), Fernandez-Cabezudo; Maria J (Abu Dhabi, AE), Torab; Fawaz (Abu Dhabi, AE)
Assignee:	United Arab Emirates University (Al-Ain, AE)
Application Number:	14/042,818
Patent Claims:	1. An intravenous pharmaceutical composition comprising: a diluent; at least 50% w/v of manuka honey diluted by the diluent; and at least one chemotherapeutic agent, wherein the chemotherapeutic agent is one of paclitaxel and any pharmaceutically acceptable salts thereof, and wherein the chemotherapeutic agent is provided in an amount of at least about 10 mg/kg of a patient to be treated. 2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a solution. 3. A method of treating skin, colon, and/or breast cancer in a patient comprising administering to the patient a pharmaceutically acceptable amount of a pharmaceutical composition comprising the composition of claim 1. 4. The method of claim 3, further comprising administering a second chemotherapeutic agent. 5. The method of claim 4, wherein the second chemotherapeutic agent is at least one of cisplatin, doxorubicin, trastuzumab, and any pharmaceutically acceptable salts thereof. 6. The method of claim 3, wherein the pharmaceutical composition is administered intravenously. 7. The pharmaceutical composition of claim 1, wherein the diluent is a sterile saline solution. 8. A unit dose or multi-dose container containing the intravenous pharmaceutical composition as claimed in claim 1. 9. The pharmaceutical composition of claim 1, wherein the composition is for enhancing survival of the patient.

Details for Patent 9,968,641

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2033-01-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2033-01-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2033-01-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.